MENU

MCRB Stock Seres Therapeutics (MCRB, $16.86) price may drop as it broke higher Bollinger Band on Aug 14, 2025

A.I.dvisor
at Tickeron.com
Loading...
MCRB - Seres Therapeutics Inc
Bollinger signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Bollinger signal
Price: $16.86
Daily change: +$0.89 (+5.57%)
Daily volume: 208.9K
Capitalization: $147.6M
Industry: Biotechnology
This price move could be a signal that MCRB may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 43 similar cases where MCRB's price broke its higher Bollinger Band, and of them led to a successful outcome. Odds of Success:

MCRB's RSI Indicator peaks and leaves overbought zone

The 10-day RSI Oscillator for MCRB moved out of overbought territory on July 21, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 instances where the indicator moved out of the overbought zone. In of the 21 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MCRB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

MCRB broke above its upper Bollinger Band on August 14, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 11, 2025. You may want to consider a long position or call options on MCRB as a result. In of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for MCRB just turned positive on August 13, 2025. Looking at past instances where MCRB's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MCRB advanced for three days, in of 258 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 101 cases where MCRB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MCRB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.435) is normal, around the industry mean (19.433). P/E Ratio (0.000) is within average values for comparable stocks, (50.965). MCRB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.945). Dividend Yield (0.000) settles around the average of (0.042) among similar stocks. P/S Ratio (0.792) is also within normal values, averaging (301.042).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MCRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
MCRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

a developer of novel treatments for diseases related to the human microbiome

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
101 Cambridgepark Drive
Phone
+1 617 945-9626
Employees
233
Web
https://www.serestherapeutics.com